Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfgang Pohl

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Drugs - Real World Outcomes|February 14, 2024
An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu<sup>®</sup> in Austrian Patients with Persistent Allergic RhinitisKatharina Marth, Andreas Renner, Georg Langmayr, et al.
Current Medical Research and Opinion|January 7, 2010
Evaluation of 3-5 months' add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real-world, observational studyWerner Schlick, Wolfgang Pohl, Karl P Pfeiffer, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 17, 2003
Effect of rocaltrol on bone mass in patients with pulmonary disease treated with corticosteroidsSiroos Mirzaei, Hubert K Zajicek, Peter Knoll, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 28, 2007
Enhanced proliferation and decreased apoptosis in lung lavage cells of sarcoidosis patientsSusanna Petzmann, Christian Maercker, Eva Markert, et al.
Pulmonary Therapy|October 23, 2020
New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical TrialJulia Romanova, Elena Chikina, Anastasia Rydlovskaya, et al.
Clinical Therapeutics|July 12, 2011
Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitisKristian Reich, Christian Gessner, Axel Kroker, et al.
Wiener Medizinische Wochenschrift (1946)|February 28, 2009
[Allergic rhinitis and its impact on asthma (ARIA update 2008). The Austrian perspective]Isabella Pali-Schöll, Wolfgang Pohl, Werner Aberer, et al.
Pulmonary Pharmacology & Therapeutics|October 10, 2019
Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probandsAndreas Renner, Julia Romanova, Boris Ferko, et al.
Wiener Klinische Wochenschrift|July 3, 2016
Diagnosis and management of asthma - Statement on the 2015 GINA GuidelinesFritz Horak, Daniel Doberer, Ernst Eber, et al.
Pulmonology|January 6, 2025
Fractional exhaled nitric oxide in a respiratory healthy general population through the lifespanChristina Bal, Caspar Schiffers, Marie-Kathrin Breyer, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Drugs - Real World Outcomes|February 14, 2024
An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu<sup>®</sup> in Austrian Patients with Persistent Allergic RhinitisKatharina Marth, Andreas Renner, Georg Langmayr, et al.
Current Medical Research and Opinion|January 7, 2010
Evaluation of 3-5 months' add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real-world, observational studyWerner Schlick, Wolfgang Pohl, Karl P Pfeiffer, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 17, 2003
Effect of rocaltrol on bone mass in patients with pulmonary disease treated with corticosteroidsSiroos Mirzaei, Hubert K Zajicek, Peter Knoll, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 28, 2007
Enhanced proliferation and decreased apoptosis in lung lavage cells of sarcoidosis patientsSusanna Petzmann, Christian Maercker, Eva Markert, et al.
Pulmonary Therapy|October 23, 2020
New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical TrialJulia Romanova, Elena Chikina, Anastasia Rydlovskaya, et al.
Clinical Therapeutics|July 12, 2011
Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitisKristian Reich, Christian Gessner, Axel Kroker, et al.
Wiener Medizinische Wochenschrift (1946)|February 28, 2009
[Allergic rhinitis and its impact on asthma (ARIA update 2008). The Austrian perspective]Isabella Pali-Schöll, Wolfgang Pohl, Werner Aberer, et al.
Pulmonary Pharmacology & Therapeutics|October 10, 2019
Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probandsAndreas Renner, Julia Romanova, Boris Ferko, et al.
Wiener Klinische Wochenschrift|July 3, 2016
Diagnosis and management of asthma - Statement on the 2015 GINA GuidelinesFritz Horak, Daniel Doberer, Ernst Eber, et al.
Pulmonology|January 6, 2025
Fractional exhaled nitric oxide in a respiratory healthy general population through the lifespanChristina Bal, Caspar Schiffers, Marie-Kathrin Breyer, et al.
Pageof 5